In the wake of COVID-19, we know you will be under more pressure than ever before to treat a large number of patients as efficiently as possible. Demand for outpatient joint replacement procedures is growing and will remain high. Successful facilities benefit from a trusted and aligned team, method for patient selection and communication, and an ally dedicated to the overall success of their TKA practice.

**Our Process, Your Success**

### Proven Savings Per Procedure

Multiple factors contribute to the savings Conformis demonstrates as compared to off-the-shelf (OTS) implant companies in each procedure:
- Quicker case turn-over
- Simplified ordering and delivery models
- Streamlined case prep for OR staff
- Reduced need for sterilization
- No annual/monthly capital expenditure for robot or associated disposable instruments

### Increase Case Volume & Efficiency

Our system is delivered as one box and one presterilized kit. This just-in-time delivery model minimizes inventory and the need for sterilization, while also reducing setup and teardown times.

### Patient Acquisition and Facility Exposure

Although currently paused during the pandemic, Conformis uses online ads to successfully target and reach surgery-ready patient prospects within a 50-mile radius of clusters of engaged, Conformis surgeons. Prospects sign up for ongoing education and also utilize our patient call center to make consult appointments with surgeons.

### Outpatient Specific Training

Regional, local and virtual training opportunities are available:
- Surgeon Visitation Program: travel to established facilities and scrub into cases, review protocols, tour the facility
- National Training Labs: experience clinical discussions with peers during didactic sessions, hands-on bioskills session hosted by our experienced surgeon proctors

### Superior Clinical Outcomes

Studies comparing Conformis to OTS TKAs have shown:
- Conformis patients discharged in under 24 hours, at a significantly higher rate than OTS patients
- Fewer Conformis patients required blood transfusions
- Fewer patients experienced adverse events at both discharge and 90 days after treatment
- $913-$2,200 total cost of care savings to the payer
- To date, more than 65 surgeons in the UK have implanted over 1,000 iTotal® CR implants with a five-year cumulative revision rate of 1.8% versus 2.2% for all other total knee replacements in the NJR.

Full studies available at [conformis.com/clinical-studies](http://conformis.com/clinical-studies)

---
